FRE Firebrick Pharma Limited
Healthcare · Drug Manufacturers - General
· website
$0.02
52wk 0.02 – 0.08
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Firebrick Pharma Limited
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$6.84M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.82
EV / EBITDA
-2.15
Price / Book
3.00
ROE
-142.7%
Operating margin
-1,320.0%
Net margin
0.0%
Total cash
$1.44M
Total debt
$0
Current ratio
6.32
Debt / Equity
—
Free cash flow
$-1.52M
Avg volume
302,527
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$293.42K
- Gross profit$104.82K
- Operating income-$2.87M
- Net income-$2.63M
- Diluted EPS-0.01
- Free cash flow-$1.86M
- Net debt-$983.35K